SM-020
Phase 2Small molecule
SM-020 is one of 55 small molecule programs targeting Skin Cancer. It is currently in Phase 2.
2
Indications
4
Total Trials
3
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
73 competitors in Skin Cancer
#DrugCompanyPhaseTrials
1Afinitor
NovartisPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Aldara
BBausch Health Americas, Inc.
Phase 3
Celebrex
PPhiladelphia Eye Associates
Phase 3
Peridex
MMedline Industries
Phase 3
Ornidyl
UUSWM, LLC (dba US WorldMeds)
Phase 3
Libtayo
RegeneronPhase 2
Iressa
AstraZenecaPhase 2
Trexall
Alnylam PharmaceuticalsPhase 2
Actos
TakedaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Keratosis2 trials
Skin Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SM-020. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- DDermBiont, Inc.